Title of article :
Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers
Author/Authors :
Jacques Bradwejn، نويسنده , , Diana Koszycki، نويسنده , , Michel Paradis، نويسنده , , Phillip Reece، نويسنده , , Joanna Hinton، نويسنده , , Allen Sedman، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 1995
Abstract :
A randomized, placebo-controlled, double-blind, three-way crossover design was used to evaluate the effectiveness of single oral 100 mg doses of CI-988, a cholecystokinin B (CCKB) antagonist, in attenuating panic symptoms induced by intravenous injection of cholecystokinin-tetrapeptide (CCK-4). Thirty healthy men received the following treatments on three separate occasions: placebo capsules/placebo, placebo capsules/CCK-4, or CI-988 capsules/ CCK-4. There was no marked difference in the number, time to onset, or duration of panic symptoms between CI-988/CCK-4 and placebo/CCK-4. There was, however, a 14% difference in sum intensity scores between these treatments that was statistically significant (p = 0.039). The symptoms most affected by CI-988 were cold chills/hot flushes, chest pain/discomfort, and anxiety/fear/apprehension. Panic attack frequency also decreased following CI-988 treatment (8/30 vs. 16/30; p = 0.035). This decrease, amid otherwise modest effects, could be explained by a preferential effect of CI-988 on the subjective experience of anxiety/fear/apprehension. Possible reasons for the relatively modest effects of CI-988 on CCK-4-induced panic symptoms are discussed.
Keywords :
CI-988 , cholecystokinin , CCKB antagonists , Panic attacks , Healthy volunteers , Anxiety
Journal title :
Biological Psychiatry
Journal title :
Biological Psychiatry